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320 Impact of impaired glucose tolerance on lung function in
adolescent cystic ﬁbrosis (CF) patients
I. Aldag1, O. Renton1, N. Wright1, C. Taylor1. 1Shefﬁeld Children’s NHS
Foundation TrustChildren’s Hospital, Cystic Fibrosis Unit, Shefﬁeld, United
Kingdom
Background: Association between CF Related Diabetes (CFRD), deteriorating
nutritional status, pulmonary health and worsening prognosis has been demonstrated
in numerous studies, but mainly in adult patients.
Methods: In line with current recommendations we performed a total of 176 annual
formal Oral Glucose Tolerance Tests (OGTT) over a 3 year period in 79 adolescent
patients. Age ranged from 9 to 18 years, mean age 13.2 years. None of the patients
were known to suffer from CFRD. We followed each patient with lung function
data and growth parameters over the next 1 to 2 years.
Results: We found 20 patients with impaired glucose tolerance on OGTT, they
showed varied disease progression. On repeat OGTT 1 year later 5 patients (25%)
had developed CFRD, 5 patients continued to have an impaired OGTT test,
5 patients had normal results and for 5 patients no data was available. Mean results
for lung function and growth data at initial OGTT and on follow up are presented in
the table. Although the trend for lung function parameters and their decline in the
CFRD Group is worse than in the Normal Group the difference is not signiﬁcant
at 5% level.
OGTT
Group
BMI% BMI% in
1 year
FEV1% DFEV1% in
1 year
FVC% DFVC% in
1 year
Normal,
mean (N)
40.3 (144) 35.4 (95) 89.2 (140) −0.5 (92) 97.0 (140) −0.8 (92)
Impaired,
mean (N)
51.3 (19) 55.3 (18) 89.5 (20) −3.4 (18) 99.3 (20) −3.0 (18)
Diabetic,
mean (N)
48.4 (10) 45.5 (8) 79.2 (10) −5.1 (8) 92.3 (10) −0.9 (8)
Conclusion: We found variable disease progression with impaired glucose toler-
ance. In the diabetic OGTT group the trend for lung function parameters is worse
than in the normal patient group, but statistically not signiﬁcant. Further studies
are necessary to establish the causative link between the aetiology of CFRD and its
clinical implications in CF patients.
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Impaired growth and respiratory function were documented prior of the establishment
of Cystic Fibrosis Related Diabetes (CFRD). Progressive insulin deﬁciency could be
the leading cause of impaired nutritional status in CF, despite normal glucose tolerance.
The aim of this study was to analyze the association between nutritional status, lung
function and insulin secretion in patients with normal glucose tolerance. Oral glucose
tolerance test (OGTT) was performed in 121 CF patients (14.4±3.1 yr). Tertiles of
insulin and c-peptide at each time of OGTT was calculated. Differences of height (H),
weight (W), BMI SDS and FEV1% were investigated in tertiles groups. Patients with
the lowest fasting blood insulin and c-peptide have lower WSDS and BMISDS. Lower
FEV1% was reported in patient with the lowest blood fasting c-peptide. The association
between basal insulin concentration and low W and BMI SDS documented in this study,
reﬂects the anabolic role of insulin in CF patients. Lower FEV1% in patients having
lowest c-peptide supports the association between insulin secretion and lung function.
Insulin deﬁciency, despite normal glucose tolerance seems to have signiﬁcant role in
clinical outcomes of CF patients.
Mean and SD of weight Standard Deviation Scores (SDS), BMI SDS and FEV1% in relation of
tertiles of blood fasting insulin and c-peptide
Banded variables Tertile, range Weight SDS BMI SDS FEV1%
Blood fasting insulin 1, 0.2−4.7mUI/mL −1.02±0.87a,b −0.72±0.87a 80.4±22.1
2, 4.8−7mUI/mL −0.37±0.96 −0.20±1.05 86.1±22.2
3, 7.1−36.3mUI/mL −0.26±1.09 0.02±1.06 91.6±23.4
Blood fasting c-peptide 1, 1.3−3.2 ng/mL −0.82±1.00a −0.56±0.93a 80.2±22.2a
2, 3.3−5.4 ng/mL −0.55±0.99 −0.32±0.96 89.7±20.6
3, 5.5−13.3 ng/mL −0.21±1.01 0.06±1.14 92.6± 0.0
Signiﬁcant differrences between tertiles have been investigated by means of ANOVA test and
Bonferroni post hoc. aSigniﬁcant difference between tertile 1 and tertile 3; bsigniﬁcant difference
between tertile 1 and tertile 2.
322* A high prevalence of cardiac autonomic dysfunction in
CF patients with and without CF-related diabetes (CFRD)
R. Rashid1, A. Tahrani2, E. Nash1, D. Honeybourne1, K. Marwa1, M. Stevens2,
J.L. Whitehouse1. 1Heart of England NHS Foundation Trust, Respiratory,
Birmingham, United Kingdom; 2Heart of England NHS Foundation Trust,
Diabetes, Birmingham, United Kingdom
Background: Cardiovascular Autonomic neuropathy (CAN) is a well recognised
complication of diabetes mellitus (DM) and is associated with increased risk of
cardiovascular complications. Although 40% of CF patients develop CF-related
diabetes (CFRD), little is known about the prevalence of CAN in CF. The aim of
this study was to assess the prevalence of CAN in CF adults with and without
CFRD.
Method: We conducted a prospective cross-sectional pilot study recruiting CF
adults cared for in our centre. CAN was assessed using non-invasive spectral
analysis of heart rate variability (ANSAR 3.0; The Ansar group inc, Pennsylvania)
at baseline, during deep breathing, during Valsalva manoeuvre and standing. The
diagnosis of CAN was made if 2 or more of the above-mentioned tests were
abnormal. Fisher’s exact test was used to compare proportions between groups.
Results: 20 patients have been recruited to date. 13 of these patients had CFRD
and were receiving treatment. CAN was found in 10 (78%) of the patients with
CFRD and in 3 (43%) of those without CFRD (p = 0.2) Early CAN was detected
in 1 (8%) of CFRD and 1 (14%) of Non-CFRD patients. 2 (15%) of CFRD, and
3 (43%) of Non-CFRD were normal on testing.
Conclusions: Preliminary data suggests that CAN is quite prevalent in CF adults
and there is a trend towards higher prevalence in those with CFRD. If this ﬁnding
is conﬁrmed in our ongoing study this may have clinical relevance in terms of both
increased cardiovascular risk, but also other complications of autonomic neuropathy
such as delayed gastric emptying.
323 Does a joint CF−diabetes team outpatient clinic improve HbA1c?
J. Lee1, J. Duckers1, L. Speight1, L. George2, R.I. Ketchell1. 1University Hospital
Llandough, Adult Cystic Fibrosis Centre, Penarth, United Kingdom; 2University
Hospital Llandough, Diabetes Centre, Penarth, United Kingdom
Background: Cystic Fibrosis Related Diabetes (CFRD) will become increasingly
common as CF populations age and the resources of both the CF and Diabetes teams
are essential for management1. We hypothesised that there would be a reduction
in the HbA1c of patients with CFRD in the year following the induction of a joint
CF–Diabetes team (CFDM) clinic.
Method: We retrospectively compared the mean HbA1cs, BMI and FEV1% of the
same patients with CFRD recorded during the year prior to and year following the
CFDM clinic introduction.
Results: 22 (11 male) patients with mean (SD) age 28.1 (5.9) years (range
21−40 years) with CFRD were studied. 21/22 patients were receiving subcutaneous
insulin. There was no statistically signiﬁcant improvement in patients’ mean HbA1c
(2005 8.8 vs 2007 8.4 P value 0.32) following the clinic commencement. The
HbA1c improved, by between 1 and 43% of baseline, in 11 (5 male) of the
22 patients. This group whose HbA1c improved had a higher mean (SD) baseline
HbA1c [10.0% (3.2) vs. 7.6% (2.0), p = 0.04] and were younger [24.8 (3.6) years vs.
31.4 (6.0) years p = 0.006] than those who didn’t improve but were otherwise similar
in terms of FEV1% and BMI (p> 0.05).
Conclusion: Patients’ mean HbA1c did not fall following CFDM introduction
but their FEV1% and BMI remained stable over two years. Interestingly, the
subgroup whose HbA1c did improve are younger. The reason for this is likely
to be multifactorial but may reﬂect the higher initial HbA1c or a greater beneﬁt
from this joint care set up.
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